Maravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024. In the quarter to June 2026, revenue grew 8.53%, EPS grew 70.4%, free cash flow grew 127.6% and total debt fell 45.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow MRVI
Maravai LifeSciences Holdings, Inc. (MRVI) P/E ratio
Maravai LifeSciences Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 168× (December 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 8.2× | (69.48%) |
| FY2021 | 26.9× | (18.28%) |
| FY2020 | 32.9× | (79.81%) |
| FY2019 | 163× | 0.00% |
| FY2018 | 163× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. | n/m |
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| URGN Urogen Pharma compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| ZYME Zymeworks Inc. compare | n/m |
| XNCR Xencor, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)